© 2005

Mechanisms of Angiogenesis

  • Matthias Clauss
  • Georg Breier

Part of the Experientia Supplementum book series (EXS)

Table of contents

  1. Front Matter
    Pages I-XIV
  2. Basic principles in physiological and pathophysiological angiogenesis

    1. Holger Gerhardt, Christer Betsholtz
      Pages 3-15
    2. Valentin Djonov, Andrew N. Makanya
      Pages 17-33
    3. Hellmut G. Augustin
      Pages 35-52
    4. Robert M.W. de Waal, William P.J. Leenders
      Pages 65-76
    5. Jean-Sébastien Silvestre, Bernard I. Lévy
      Pages 77-93
    6. Kathy D. Miller, Christopher J. Sweeney, George W. Sledge Jr
      Pages 95-112
  3. Cellular and physical mechanisms of blood vessel growth

    1. Christer Betsholtz, Per Lindblom, Holger Gerhardt
      Pages 115-125
    2. Leni Moldovan, Nicanor I. Moldovan
      Pages 127-146
    3. Hiromi Nishimura, Takayuki Asahara
      Pages 147-154
    4. Jalees Rehman
      Pages 155-161
    5. Matthias Heil, Wolfgang Schaper
      Pages 181-191
  4. Molecular mechanisms of angiogenesis

    1. Gavin Thurston, John S. Rudge, Ella Ioffe, Nicholas Papadopoulos, Christopher Daly, Srilatha Vuthoori et al.
      Pages 233-245
    2. Victor W.M. van Hinsbergh, Pieter Koolwijk, Klaas Hoekman
      Pages 247-266
    3. Ian Zachary
      Pages 267-300
  5. Back Matter
    Pages 301-321

About this book


Is it advisable to go back from bedside to the bench? During the last decade, few topics encountered such a broad interest in bio- gy and medicine as angiogenesis. The amazing ability of the body to restore blood flow by induction of blood vessel growth as part of an adaptive process has alarmed physicians dealing with diseases in which angiogenesis is either exaggerated (as in tumors) or too slow (as in ischemic diseases of heart and brain). Not surprisingly, pro- and antiangiogenic strategies have found their way into clinical trials. For instance, for the USA, the NIH website in early 2004 displayed 38 clinical studies involving either pro- or antiangiogenic th- apies. Given the expected overwhelming wealth of clinical data, the question may be asked whether further exploration of biological mechanisms is required or whether results from the bedside are instructive enough to proceed. This question depends also on the progress of pro- and antiangiogenic clinical trials. In the following, I give a short overview about some of the progress that has been made in this field. Since Judah Folkman proposed antiangiogenic tumor therapy thirty years ago, it has become increasingly evident that agents which interfere with blood vessel formation also block tumor progression. Accordingly, antiangiogenic therapy has gained much attention as a potential adjunct to conventional c- cer therapy.


Angiotensin II angiogenesis atherosclerosis blood vessel bone cells endothelium heart hormones macrophages morphogenesis regulation smooth muscle tumor

Editors and affiliations

  • Matthias Clauss
    • 1
  • Georg Breier
    • 2
  1. 1.Department of Cellular and Integrative PhysiologyIndiana Center for Vascular Biology and MedicineIndianapolisUSA
  2. 2.Institute of PathologyUniversity Clinic Carl Gustav Carus TU DresdenDresdenGermany

Bibliographic information

Industry Sectors
Health & Hospitals
Consumer Packaged Goods